James S. Tomlinson, MD, PhD

James S. Tomlinson, MD, PhD

Associate Professor, Department of Surgery
Chief of Surgical Oncology, Veterans Affairs Greater Los Angeles Medical Center
Director, Veterans Affairs Greater Los Angeles Cancer Center

Specialty

Surgical Oncology

Institutional Affiliation

Ronald Reagan UCLA Medical Center
Greater Los Angeles Veterans Affairs Medical Center

Languages

English

Education

Fellowship

Surgical Oncology, Memorial Sloan-Kettering Cancer Center, 2003 - 2005

Internship

General Surgery, UCLA School of Medicine, 1995 - 1996

Degrees

PhD, UCLA Department of Molecular and Cellular Pathology, 2009
MD, University of Pennsylvania School of Medicine, 1995

Residency

General Surgery, UCLA School of Medicine, 1996 - 2003

Board Certification

Surgery, American Board of Surgery, 2004

Contact Information

Clinical Interests

Pancreatic Cancers, Liver Tumors, Gastrointestinal Cancers

Scientific Interests

Dr. James Tomlinson's research is focused on developing novel engineered antibody fragments as targeting agents against pancreas cancer. He hopes to first translate these antibodies as imaging agents and then secondarily develop these same agents into radioimmunotherapeutics. Additionally, he is involved in collaborations regarding nanoparticle targeting and in vivo click chemistry reactions to enhance targeted therapies.

Highlighted Publications

McCabe KE, Liu B, Marks JD, Tomlinson JS, Wu H, Wu AM. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol. 2012 Jun;14(3):336-47.

Girgis MD, Kenanova V, Olafsen T, McCabe KE, Wu AM, Tomlinson JS. Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. J Surg Res. 2011 Oct;170(2):169-78. Epub 2011 Apr 20

Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer. Int J Mol Imaging. 2011 Sep 6;2011:834515.

Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment. EJNMMI Res. 2011 Nov 7;1(1):24.

Wasif N, Ko CY, Farrell J, Wainberg Z, Hines OJ, Reber H, Tomlinson JS. Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol. 2010 Sep;17(9):2312-20. Epub 2010 Apr 27